Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Reports revenue RMB 980.7M vs. RMB 221.9M last year. Dajun Yang, CEO, said, “As we reflect on our achievements in 2024, I am delighted to ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...